Taiwan Bio Industry Organization (Taiwan BIO)

<TBIO Activity> Our Secretary General, Dr. Wallace Lin, is at BIO-EUROPE 2024, feel free to look us up and request a meeting through the partnering system!

<Taiwan Bio Industry Organization - Election of the 18th Board of Directors, Chairman, and Supervisors> Lee-Cheng Liu, Chairman of 台康生技股份有限公司 (EirGenix) Elected as New Chairman === The Taiwan Bio Industry Organization (Taiwan BIO) held its general meeting on Oct. 21 to elect its 18th Board of Directors, Chairman and Supervisors. As a result, Lee-Cheng Liu, Chairman of one of Taiwan's leading #CDMO firms, 台康生技股份有限公司 (EirGenix), was elected as the new Chairman. The Vice Chairman positions were taken by Chris Tsai, Chairman of 訊聯生物科技股份有限公司 (Bionet Corp.), and Jo Shen, Venture Partner at Vivo Capital. Nine new members have joined the board of directors and supervisors, including: 👉David Chang, CEO, Taiwan Bio-Manufacturing Corporation; 👉Calvin Tsai, CEO, Orient Europharma; 👉Lin Shih-Chia, General Manager, TaiAn Technologies Corporation; 👉Wu Han-Chung, Director, Biomedical Translational Research Center (BioTReC), Academia Sinica; 👉Eric Chuang, Industrial Technology Research Institute (工研院), Deputy Director and Director, Biomedical and Medical Technology Institute; 👉Chen Hsiu-Hui, Acting CEO, 生技中心 (DCB); 👉Hsieh Hsing-Pang, National Health Research Institutes (NHRI), Director of Biotechnology and Drug Research Institute; 👉Colin Kao, COO of 浩鼎生技股份有限公司 (OBI); and 👉Simon Tsai, National Health Research Institutes (NHRI), Director, Technology Transfer & Incubation Center. Since its establishment in 1989, Taiwan BIO currently includes 164 organizations, representing 4,000 individuals from industry, government, academic, and research, making it not only the longest-standing bio-industry association in Taiwan but also the most comprehensive. This term's board members include key figures from the biomedical industry, academic research institutions, and the venture capital community. Newly elected Chairman Lee-Cheng Liu emphasized underscored the importance of advancing Taiwan's biomedical industry on a global scale. Through collaborations with the global Biotechnology Innovation Organization (BIO) in recent years, Taiwan BIO has successfully hosted BIO Asia–Taiwan, now the largest biotech event in Asia. Additionally, Taiwan BIO's Secretary General Wallace Lin was elected Vice Chair of the International Council of Biotechnology Associations (#ICBA) this year, further aiding Taiwan's entry into the global biomedical market and strengthening international connections. Liu hopes to work together with the board and all Taiwan BIO members to actively participate in shaping industry policies, overcoming obstacles and bottlenecks, and helping the biotech industry reach new heights. For the full news release & list, please see: https://lnkd.in/gDNRuvuU

<TBIO Activity> 2024 Taiwan Bio Industry Organization Annual Meeting The Taiwan Bio Industry Organization (TBIO) held its 18th Annual General Meeting & Banquet on the 16th, co-organized by PwC Taiwan, under the theme "The Path to Biotech Innovation Growth." The event began with a discussion on "Global Trends and Outlook for the Biomedical Industry" and further explored the topic "From Startup Funding to IPO: Prospects for Taiwan's Biotech Capital Market." Experts from industry, investment, and academia were invited to participate in focused discussions on "AI-Driven Biomedical Innovation" and "Opportunities and Challenges in Connecting International Capital with the Health Taiwan Vision," engaging in in-depth exchanges to share a future road map for the development of Taiwan's biomedical industry. Guest speakers including: 👉 PwC Taiwan Chairman & CEO - Joseph Chou 👉National Development Council Deputy Minister - Fang-Guan Jan 👉Development Center for Biotechnology (DCB), Department of Industrial Information & Analysis, Co-Project Leader - Yu-Ting Jeng 👉PwC Taiwan Practicing Accountant - Pei-Chuan Huang 👉Genesis Genetics Asia (GGA) CEO - Christopher Tsai 👉AnHorn Medicines Founder and President - Chu-Chiang Lin 👉NVIDIA Biotech and Healthcare Solutions Architect - Ying-Ja Chen 👉Biomedical Translation Research Center , Academia Sinica, Research Fellow and CEO - Hsiu-Ming Shih 👉 Montreal International Foreign Investment Business Development Director - Yun Li 👉PwC Taiwan Biotech Industry Lead Accountant - Jasmine Yu 👉Taiwan Stock Exchange Corporation Listing Department I Deputy Manager - Hsueh-Chen Chang 👉CDIB BioScience Fund General Manager - Hsin-Fang Wu 👉BE Capital & Accelerator Managing Partner - Yen-Yu Chen After the exciting afternoon forum, more than 350 professionals from various sectors of Taiwan's biotech industry gathered for the evening banquet, engaging in extensive networking and interaction. The event also featured speeches from Cabinet Minister Shih-chung Chen and Deputy Director-General of the Industrial Development Bureau, MOEA, Pei-Li Chen. Additionally, Lee-Chung Chien, Chairman of the Taipei Exchange, shared insights on how the exchange can support the sustainable development of the biotech industry.

<TBIO Activity> Vice President Hsiao met with the "2024 Taiwan BIO Award" winners on Oct. 15, acknowledging their dedication to the industry and their achievements across various fields. She emphasized that the government has continued to support the biotechnology sector through various policies in recent years, aiming to see the industry play a more critical role both in Taiwan and globally. She expressed hope for continued efforts to drive the industry's growth, making it a significant force in promoting public health. During her speech, the Vice President said she was honored to welcome the outstanding biotech companies and the representatives. She also thanked the "Taiwan Bio Industry Organization" for inviting her to attend this year's "BIO Asia–Taiwan" exhibition in July, which was an eye-opening experience. The Vice President highlighted the importance of the biotechnology industry to Taiwan, stating that through meetings and exchanges with industry professionals and scholars, as well as attending industry-related events, she has observed Taiwan's continuous progress and development in the biotech sector. Over the past few years, the government has consistently supported the industry through various policies, hoping that the biotech industry can play a more critical role both in Taiwan and on the global stage. She pointed out that due to the pandemic, there were disruptions in the global supply chain, and the world was competing for essential medical supplies. This situation underscored the complexity of global supply chains and reminded us that a strong local biotechnology industry is crucial, whether in meeting the expectations of the people or fulfilling the government's responsibility for public health. In conclusion, the Vice President congratulated all award winners for their contributions and cross-disciplinary achievements in the biotech industry, including areas such as medical devices, pharmaceuticals, research and development, agriculture, and health foods. She expressed hope for continued efforts to drive the industry's development, making it a key force in promoting public health. News Release (in Chinese): https://lnkd.in/gBCg3nZj The 2024 Taiwan BIO Award Winners: Bonraybio Corporation Lotus Pharmaceutical Co., Ltd PharmaEssentia Pharmosa Biopharm Inc TSH Biopharm Corporation Ltd Steminent Biotherapeutics Onyx Healthcare 明基透析科技 (BenQ Dialysis Technology Corp.) Acepodia ImmunAdd Inc. Sunhawk Vision Biotech (視航生物) Elixiron Immunotherapeutics BioGend Therapeutics (TWSE 6733) BRAXX Biotech Co., Ltd. Protect Animal Health Inc. Formosa Pharmaceuticals, Inc. TaiGen Biotechnology (太景生物) HippoScreen Neurotech Corp. Syngen Biotech

<TBIO Activity> BioJapan 2024 #BioJapan2024 (by BioJapan / JTB Communication Design) kicked off on Oct. 9 at the Pacifico Yokohama Convention Center for 3 days till the 11th, featuring over 200 forums, seminars and corporate presentations, with 460 companies exhibiting, and a total of 1,486 organizations participating in partnering. A record-breaking number of attendees was reached on the first day, and the organizer noted that this year's BioJapan has expanded by more than 20% compared to previous years. Under the organization and call of 生技中心 (#DCB, Development Center for Biotechnology) and #BPIPO (Biotechnology and Pharmaceutical Industries Promotion Office, MOEA), the Taiwan Pavilion has nearly 60 industry, government, academic and research units participated in BioJapan 2024 exhibition and partnering, which surpassed the previous years. The Taiwan Pavilion Exhibitors: ACRO Biomedical Co., Ltd. / Amaran Biotechnology, Inc. / Bora Biologics CO., LTD. / Department of Industrial Technology, MOEA / Development Center for Biotechnology / FEBICO遠東生技 / King's Ground Biotech / KriSan Biotech Co., Ltd. / Level Biotechnology Inc. (3118) / LumiSTAR Biotechnology, Inc. 昱星生物科技 / 國家科學及技術委員會 / PELL Bio-Med Technology CO.,LTD. / Steminent Biotherapeutics / TaiGen Biotechnology LTD. / Taiwan Bio Industry Organization / 向榮生技UnicoCell Biomed The exhibition officially ended yesterday (10/11). The total number of visitors during the three-day exhibition was: 18,000+. Well done, Taiwan Delegation, and welcome home!

<TBIO Activity> BioJapan 2024 The #BioJapan Taiwan delegation had a packed schedule yesterday (10/8), though the exhibition has not yet started. ✨Visitation of Shonan iPark & participating in its Global Showcase event✨ 👉 A group of 20 companies/organizations from Taiwan along with other 35 companies from the U.S., South Korea, France, China, Switzerland, Sweden, and Ireland to visit #iPark and interacting with the Japanese companies located there during its Global Showcase event. 👉 Shonan iPark is one of Japan's largest life science parks, covering 300,000 square meters, which was opened to the public in April 2018 by Takeda Pharmaceutical's Shonan Research Center, it is now managed by iParkInstitute Co. Ltd. 👉 There are 116 companies located within iPark, 62 of which are members, representing various sectors such as #pharmaceuticals, #startups, R&D in new drug, R&D business support, #AI, and #trade. // ✨ Participating the APAC DA-EWG Meeting led by the Japan Pharmaceutical Manufacturers Association (JPMA)✨ 👉 A total of 18 Taiwanese companies/organizations participated, engaging in discussions with 10 Japanese representatives. 👉 The Japan Pharmaceutical Manufacturers Association (#JPMA) comprises leading Japanese pharmaceutical companies, including #Takeda Pharmaceutical Co., #Chugai Pharmaceutical Co., #Eisai Co., #SumitomoPharma Co., #AsahiKasei Corp., #Astellas Pharma Inc., #MeijiSeika Pharma Co., #Shionogi & Co., among other renowned firms. 👉 The Asia Partnership Conference of Pharmaceutical Associations (#APAC) is an organization formed by 13 pharmaceutical R&D associations from 11 Asian countries. Its goal is to promote and accelerate the development and marketing of innovative drugs in Asia. Since its establishment in 2012, APAC has hosted annual meetings, serving as a platform for communication and exchange among industry, government, and academia. The Drug Discovery Alliance Expert Working Group (#DAEWG) was initiated by JPMA in 2013 to enhance new drug development in Asia and strengthen the region’s pharmaceutical innovation capabilities.

<TBIO Activity> TBIO will join the upcoming #BioJapan2024 (by BioJapan / JTB Communication Design) with Biotechnology and Pharmaceutical Industries Promotion Office (#BPIPO) and the following companies at the Taiwan Pavilion (➡️Booth No. B-56): Amaran Biotechnology, Inc. 向榮生技UnicoCell Biomed FEBICO遠東生技 #TaiGenBiotechnology (太景生物科技股份有限公司) LumiSTAR Biotechnology, Inc. 昱星生物科技 Bora Pharmaceuticals (Bora Biologics) King's Ground Biotech Level Biotechnology Inc. (3118) 生技中心 (Development Center for Biotechnology) PELL Bio-Med Technology (沛爾生醫)  KriSan Biotech Co., Ltd. Steminent Biotherapeutics ACRO Biomedical Co., Ltd. Look up for more Taiwanese companies as Exhibitors and in Partnering: https://lnkd.in/g9wg647u.. Taiwan Pavilion Activities: 👉 Thursday Oct. 10 at 10:15-11:30 Main Stage Seminar - Biocluster Summit "Taiwan's Key Role in Building Successful Asian Biotech Ventures" by Dr. Michael Huang, Acting Director, BPIPO 👉 Thursday Oct. 10 at 16:00-17:00 HAPPY HOUR at the Taiwan Pavilion Please feel free to stop by at booth ⭐B-56⭐ to say hi, or schedule a partnering meeting with us!

Taiwan Life Sciences Biweekly - Sept. 30, 2024 🔔 合一生技 Oneness Biotech Co Ltd announced to apply for US Biomedical Advanced Research and Development Authority (BARDA) for a Project NextGen grant for its broad-spectrum nucleic acid-based COVID-19 treatment, SNS812. 🔔 工業技術研究院 and Amicoipet Biotech's Smart Pet Collar Bags Gold Medal at Concours Lepine International 2024 in Paris, France. 🔔 Taiwan's National Health Research Institutes (#NHRI) and National Taiwan University Hospital study finds that exosomes can detect breast cancer metastasis. 🔔 宏碁智醫 Acer Medical, a subsidiary of computer maker Acer Group, targets Thailand market, announcing that its AI-powered eye screening software, VeriSee AMD, has received approval from Thailand's Food and Drug Administration. 🔔 Newsweek announced its 2025 rankings of the World's Best Smart Hospitals, with 臺中榮總 ranked among the Top 100 smart hospitals worldwide as the first hospital in Taiwan to receive such recognition. 🔔 The Max Planck Society in Germany officially announced the appointment of Associate Researcher Hsueh Yan-Ping from Taiwan's 中央研究院 of Molecular Biology as one of the six department heads at the Max Planck Institute for Biology Tübingen (MPI Biology TŸbingen). 🔔 台康生技股份有限公司 (TW: 6589) held an investor conference where Chairman Liu Li-cheng announced that their first-generation breast cancer biosimilar, Trastuzumab (EG12014), is on track to receive US regulatory approval by year-end, with a high-dose version planned for next year. 🔔 Senhwa Biosciences, Inc. Announces IND Submission to US FDA for Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors sponsored by NCI. 🔔 A Taipei Medical University research team has found that the hemoglobin concentration levels resulting from fecal occult blood tests (FOBT) can predict the risk and mortality of colorectal cancer, and could be used to suggest the interval between screenings. 🔔 PlexBio Co., Ltd. collaborates with Brazil's Biomedica Brazil to target precision medicine market. Read More: https://lnkd.in/ghAVEeFq

【生物產協第十八屆第一次會員大會 生技創新茁壯之路 -- 論壇暨晚宴】 台灣生物產業發展協會將於113年10月16日(三)舉辦會員大會暨「生技創新茁壯之路」論壇暨晚宴活動。 ✨ 下午論壇與資誠聯合會計師事務所 共同合辦，將有「全球生醫產業趨勢與展望」、「新創募資到IPO:台灣生醫資本市場展望」之專題演講，並於專題演講後安排「AI技術驅動生醫創新力量」、「健康臺灣願景中鏈結國際資金的機會與挑戰」兩場焦點座談會。分別邀請 #訊聯基因數位股份有限公司 蔡政憲執行長、#資誠聯合會計事務所 游淑芬生醫產業主持會計師 擔任主持人，並邀請 #台灣證券交易所 及產業專家們包括 #安宏生醫 林助強董事長、#NVIDIA 陳映嘉架構師...等等擔任與談貴賓到場分享。 ✨晚宴則特別邀請 #證券櫃檯買賣中心 簡立忠董事長進行專題分享。 ❇️ 兩場活動均開放予非會員報名與會！歡迎您把握現場交流機會，踴躍參與。 ｜主辦單位：社團法人台灣生物產業發展協會 ｜協辦單位：資誠聯合會計師事務所 ｜時間：113年10月16日(三) ｜地點：台大醫院國際會議中心 (台北市徐州路二號) ※第十八屆理事、監事選舉時間: 13:30~19:00 @202廳(2F) ※會議時間: 13:30~17:20 @101廳(1F) ※晚宴時間: 18:00~21:00 @201廳(2F) ｜費用： 下午論壇免費 晚宴費用:個人餐券 會員$2,000元; 非會員$2,500元 晚宴團體認桌 會員$20,000 ; 非會員$25,000元 (認桌每桌10位，認桌單位享有Logo露出於佈置物與手冊) ｜報名： https://lnkd.in/g6HnazQT ｜活動網頁：https://lnkd.in/gXCDSwuU

<TBIO Activity> Today (Oct. 1), we had the honor to welcome Dominic Trindade, Regional General Manager of Australian Trade and Investment Commission, and Christopher Lim, Senior Trade and Investment Commissioner, Deputy Representative of Australian Office Taipei to our office. Our General Secretary, Dr. Wallace Lin, took the opportunity to introduce the overview of Taiwan's Biotech and Pharmaceutical CDMO Industry, as well as to elaborate the close collaborations between TBIO and Australian Office Taipei, hoping for more cooperation opportunities in 2025.